Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/25/2025

Beta-Blocker Selection and Management

Introduction to Beta-Blocker Therapy

  • The European Society of Cardiology recommends bisoprolol as a first-line beta-blocker due to its superior beta-1 selectivity and favorable side-effect profile 1

Rationale for Beta-Blocker Selection

  • Non-selective beta-blockers, such as propranolol and timolol, carry a higher risk of bronchospasm and are not recommended for patients with COPD or asthma 2, 3
  • The American Heart Association suggests that beta-blockers with intrinsic sympathomimetic activity should be avoided due to insufficient heart rate reduction and lack of benefit in heart failure 4, 5

Alternative Beta-Blockers and Clinical Context

  • Carvedilol may be preferred in heart failure patients requiring additional vasodilation, but it carries a higher risk of hypotension and requires twice-daily dosing 6, 7
  • Labetalol is recommended for pregnancy-related hypertension due to its proven safety profile 2, 3, 8

Agents to Avoid

  • Atenolol should be avoided due to its inferior outcomes in major trials and metabolic effects similar to non-selective agents 4, 5
  • Non-selective agents pose an unacceptable risk in patients with reactive airway disease 2, 3

Common Pitfalls to Avoid

  • The American College of Cardiology recommends assessing for COPD or asthma before initiating any beta-blocker, and using beta-1 selective agents like bisoprolol in patients with cardiovascular disease 2, 3, 8
  • Patients with classical pulmonary asthma may worsen with non-selective agents or those with low beta-1 selectivity 3, 5
  • The European Society of Cardiology advises against using beta-blockers in marked first-degree AV block, second- or third-degree heart block without pacemaker, severe LV dysfunction with active decompensation, or hemodynamic instability 9, 10
  • The American Heart Association recommends avoiding intravenous beta-blockers in patients at high risk for cardiogenic shock 10
  • Beta-blockers may mask hypoglycemia symptoms in type-1 diabetes or insulin-treated patients, and monitoring for bradycardia is recommended in elderly patients 3, 4, 5, 8

REFERENCES

6

Protocol for Switching from Metoprolol Tartrate to Carvedilol CR in Post-CABG Patients [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

7

Switching from Metoprolol Tartrate to Carvedilol in HFrEF with Persistent AFib Post-CABG [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025